Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Thousands of small fish defy gravity to climb Congo waterfall - 2'You're no longer my sister' - rows erupt as war divides Iranian families
- 3Iran fires one of largest barrages in weeks ahead of Passover
- 4Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- 5Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- Flu cases spiking this holiday season, CDC data shows
- Ukrainian drones hit all three Baltic States − did Russia redirect them?
- Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- Most loved Well known Accessory Styles For 2024
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Fears of global aluminum shortages intensify
- Courageous Climbing: Trails and Stuff for Outside Lovers
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- Well known Worldwide Caf\u00e9s to Experience
